Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Mar 27, 2026-

AstraZeneca’s novel COPD drug secures double win in Phase III

GD analyst, Vinie Varkey notes that AstraZeneca's tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.The post AstraZeneca’s novel COPD drug secures double win in Phase III appeared first on Clinical Trials Arena.